1
2
Chengdu, China, May 19, 2023 /PRNewswire/ — On May 17, 2023, the bivalent recombinant protein (Bivalent) COVID-19 vaccine (cells Sf9) and the trivalent Covid-19 vaccine (cells Sf9) developed by the Chinese Medical Center WestVac Biopharma of Sichuan University, has obtained “Clinical Trial Approval of Drugs” from the China National Medical Products Administration for the prevention of variant virus. XBB recently published. These two new vaccines will be marketed quickly to protect against a variant XBB Currently deployed upon completion of necessary clinical trials. These two vaccines are also the first two COVID-19 vaccines in the world to begin clinical trials specifically to prevent variants such as XBB.
The Joint Prevention and Control Mechanism of the State Council held a press conference in early May 2023. During the meeting, it was noted that with the increase in internal and external interaction between China and other countries, the major epidemiological variables of coronavirus in the world, especially in China, have increased significantly. According to the monitoring data [1]The initial epidemiological variants of the COVID-19 virus in China have developed into a chain XBB. In this context, the center is used WestVac Biopharma International Advanced Insect Cell Recombinant Protein Vaccine Platform for the Development of a Recombinant Protein Vaccine against COVID-19 (XBB + prototype strain) (hive SF9) Coviccine® Recombinant bivalent and trivalent against COVID-19 (XBB+BA. 5 + delta variant) triple protein vaccine (cell Sf9). a vaccine WestVac They are necessary to prevent current variants of XBB They contribute significantly to the ongoing management of the COVID-19 pandemic.
®Coviccine bivalent recombinant anti-COVID-19 (bivalent)XBB + Prototype) Vaccine Protein (cell Sf9)
Bivalent Recombinant Protein Vaccine (COVID-19)XBB + prototype) (cell Sf9) is an upgraded version of ®Coviccine Recombinant COVID-19 Vaccine (cell Sf9) that I developed WestVac Biopharma. Studies have shown that the vaccine caused a high incidence of neutralizing antibodies against multiple sub-variants, incl XBB.1.5 And XBB1.16 And XBB1.9.1 And XBB.2.3 And BA.5 And BF. 7 And BQ. 1 [1]indicating that the vaccine is an effective universal vaccine against multiple strains, especially with a significant increase in neutralizing antibodies against series variants. XBB.
trivalent protein vaccine (XBB+BA.5+Delta) against Covid-19 (cell Sf9)
Taking advantage of the rapid response of the internationally advanced insect cell expression platform in producing the recombinant protein vaccine, the Center WestVac Biopharma and its subsidiary named WestVac Biopharma (Guangzhou) to establish a vector for the trivalent protein vaccine (XBB+BA.5+Delta) against Covid-19 (cell Sf9), and produced trivalent protein vaccines of high purity and high quality for human use. The subunit vaccine antigen is precisely designed based on a targeting construct S-RBD and HR proteins for covid-19 sub-variants XBB And BA.5, and can self-assemble into stable ternary protein molecules. Studies have shown that the vaccine caused a higher amount of neutralizing antibodies against multiple sub-variants, incl Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75indicating that it is a broad-spectrum vaccine against many sub-variants prevalent at home and abroad [1].
About WestVac Biopharma
WestVac Biopharma It is an innovative biopharmaceutical company integrating vaccine research and development, production and sales system with an annual production capacity of 1.1 billion doses of vaccine. Center has been selected WestVac Biopharma Successfully listed as Unicorn companies from 2021 to 2023. In December 2022, the ® vaccine was approvedCoviccine By the National Emergency Use Authority, it is included in the vaccine procurement list in the bidding process in more than 20 provinces in China.
the reviewer:
Image – https://mma.prnewswire.com/media/2080167/1.jpg
Photo – https://mma.prnewswire.com/media/2080168/2.jpg
WestVac BioPharma Co., Ltd. SOURCE
